Cardinal Health reports its fiscal fourth-quarter results on August 11 with one of the clearest bullish consensus builds seen across healthcare distributors this earnings season.
The analyst story is the standout heading into the print. Multiple bellwether firms lifted their price targets in the weeks before the release, and the direction has been almost uniformly upward. UBS raised its target to $274 from $260 while keeping its Buy rating, Citigroup moved to $265 from $245, and B of A Securities pushed to $260 from $240 — all within the past month. TD Cowen has a $275 target. The consensus mean lands at $252.40, roughly 7% above the current price of $236.40, suggesting the Street sees additional room despite a stock that has already gained more than 30% year-to-date. JP Morgan is the lone holdout, sitting at Neutral with a $215 target — the sole visible bear among the recent movers. The bull case centres on free cash flow growth, expanding positions in radiopharmaceuticals and precision medicine, and a reliable capital return program. Bears point to drug-pricing regulatory risk, intensifying competition in pharmaceutical distribution, and exposure to commodity costs in the medical products segment.
Options positioning leans modestly more defensive than usual, but not alarmingly so. The put/call ratio has drifted up to 0.78, about one standard deviation above its 20-day average of 0.74. That's a mild tilt toward downside protection — nothing like the crowded hedging seen ahead of some recent healthcare prints — and leaves the PCR comfortably below its 52-week high of 1.04. Short interest reinforces that reading: at roughly 2.9% of the free float, it's low and trending lower, down about 27% from a month ago. Borrow availability remains exceptionally loose, with nearly 200 million shares available versus the roughly 6.9 million currently shorted. There is no meaningful short-side pressure entering the quarter.
Past earnings reactions introduce some caution. After the May 1 print, the stock rose 2.2% on the day but then gave back nearly 5% over the following five sessions. The April 30 result was more immediately punishing — a 3.7% same-day decline and nearly 9% lost over the subsequent week. EPS momentum is a counterweight: Cardinal Health ranks in the 94th percentile on 30-day EPS momentum and 98th percentile on 12-month forward EPS growth expectations, signalling that estimate revisions have been running hard in its favour. Closest peers McKesson and Cencora have underperformed Cardinal Health meaningfully over the past week, with MCK roughly flat and COR up about 4%, offering little directional read-through.
The August 11 print will test whether the unusually broad analyst upgrade cycle of the past month reflects genuine fundamental momentum — or whether the stock's 30%-plus year-to-date run has pulled forward the upside the Street is now chasing with higher targets.
See the live data behind this article on ORTEX.
Open CAH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
